Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.
The localization of neutralization determinants within the envelope glycoproteins of human immunodeficiency virus (HIV) has been largely achieved by immunizing small animals in conjunction with Freund's adjuvant. However, for eventual use in humans, candidate HIV vaccine components must also be efficacious in a nontoxic formulation. We describe here the production of hybrid Ty viruslike particles carrying the major neutralizing domain of HIV and demonstrate the induction of high-titer virus-neutralizing antibodies and an HIV-specific T-cell proliferative response after immunization in conjunction with aluminum hydroxide. As aluminum hydroxide and aluminum phosphate are the only adjuvants currently licensed for use in humans, these observations have implications for the development of an effective vaccine against HIV.
Griffiths
J C
JC
British Bio-technology Ltd., Cowley, Oxford, United Kingdom.
Berrie
E L
EL
Holdsworth
L N
LN
Moore
J P
JP
Harris
S J
SJ
Senior
J M
JM
Kingsman
S M
SM
Kingsman
A J
AJ
Adams
S E
SE
D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000917:Antibody Formation; D001483:Base Sequence; D001666:Binding Sites, Antibody; D005620:Freund's Adjuvant; D005822:Genetic Vectors; D006678:HIV / Q000235:genetics / Q000276:immunology*; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology* / Q000648:ultrastructure; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011487:Protein Conformation; D011817:Rabbits / Q000276:immunology
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D005620:Freund's Adjuvant